Filing Flows › AIM ImmunoTech (AIM) › Q2 2026
AIM ImmunoTech (AIM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
AIM ImmunoTech (AIM) reported revenue of $26K for the second quarter 2026 (Q2 2026), +4% from a year earlier and +18% from the quarter before.
AIM ImmunoTech, Q2 2026: revenue $26K (+4% year over year), net loss $3.8M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26K | +18% | +4% |
| Operating profit | −$3.5M | — | — |
| Net earnings | −$3.8M | — | — |
| Operating cash flow | −$4.6M | — | — |
What changed
Revenue was $26K in Q2 2026, up 4% year over year and up 18% from the previous quarter.
Operating costs exceeded revenue by $3.5M, an operating margin of -13511.5%. Total costs grew 32% against revenue growth of 4%. The fastest-growing cost line was General & admin (+98%). The quarter ended with a net loss of $3.8M, wider than the previous quarter's $3.0M loss.
Operating cash flow was −$4.6M. Non-cash charges added back $44K of depreciation and amortization. Working capital and other items used $846K.
Questions
What was AIM ImmunoTech's revenue in the second quarter 2026?
AIM ImmunoTech (AIM) reported revenue of $26K for the second quarter 2026 (Q2 2026), +4% from a year earlier and +18% from the quarter before.
Source: AIM ImmunoTech 10-Q on SEC EDGAR.